Krystal Biotech delivered strong Q1 2026 results, with Vyjuvek sales up 32% YoY to $116.4M and gross margin expanding to 95%.

Biotech stock Avalo Therapeutics skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment.

Q VYJUVEK global revenue and $846.7 million since launchEnrollment complete in KB803 (corneal abrasions in DEB patients) ...

Corcept Therapeutics Inc. (NASDAQ: CORT) is one of the 10 best biotech stocks with highest upside potential.

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its ...

Andrew Hillman Grant for Biotech Introduces National Opportunity for Undergraduate Talent to Explore the Future of ...

Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for ...

The biggest biotech deal so far in 2026 was announced in April. Pacts were signed over ADCs, small molecules, and AI ...

The U.S. biotech and life sciences job market in early 2026 is showing tentative stabilization after years of layoffs and funding constraints, with hiring concentrated in execution-critical and ...

In Salt Lake City, biotech founders new and seasoned reflect on ways to ride out the industry’s challenges, such as sending ...

Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, ...